Bibliography
- Calhoun DA, Jones D, Textor S, & American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:510-26
- Schlaich MP, Sobotka PA, Krum H, Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-4
- Scheffers IJ, Kroon AA, Schmidli J, Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56:1254-8
- Weber MA, Black H, Bakris G, A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31
- Nakov R, Pfarr E, Eberle S, Heat Investigators. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002;15:583-9
- Bakris GL, Lindholm LH, Black HR, Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010;56:824-30